Adamas Pharmaceuticals Profit Margin 2013-2019 | ADMS

Current and historical gross margin, operating margin and net profit margin for Adamas Pharmaceuticals (ADMS) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Adamas Pharmaceuticals net profit margin as of September 30, 2019 is -215.09%.
Adamas Pharmaceuticals Annual Profit Margins
Adamas Pharmaceuticals Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.156B $0.034B
Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $59.615B 10.87
Teva Pharmaceutical Industries (TEVA) Israel $10.679B 4.35
Bausch Health Cos (BHC) Canada $9.635B 6.37
Mylan (MYL) United States $8.914B 4.00
Dr Reddy's Laboratories (RDY) India $6.395B 16.78
ASPEN PHARMACR (APNHY) South Africa $3.552B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.149B 11.12
Amphastar Pharmaceuticals (AMPH) United States $0.810B 42.07
Homology Medicines (FIXX) United States $0.532B 0.00
Voyager Therapeutics (VYGR) United States $0.528B 0.00
Akorn (AKRX) United States $0.527B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.510B 0.00
CymaBay Therapeutics (CBAY) United States $0.371B 0.00
Assembly Biosciences (ASMB) United States $0.365B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.245B 0.33
Sol-Gel Technologies (SLGL) Israel $0.156B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.149B 0.00
Teligent (TLGT) United States $0.034B 0.00
China Pharma Holdings (CPHI) China $0.011B 0.00